Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Generic warfarin: implications for patient care.

Wittkowsky AK.

Pharmacotherapy. 1997 Jul-Aug;17(4):640-3. No abstract available.

PMID:
9250543
2.

Generic substitution: issues for problematic drugs.

Henderson JD, Esham RH.

South Med J. 2001 Jan;94(1):16-21. Review. Erratum in: South Med J. 2001 Dec;94(12):1235.

PMID:
11213935
3.

Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins.

Vercaigne LM, Zhanel GG.

J Pharm Pharm Sci. 1998 Sep-Dec;1(3):92-4. Review. No abstract available.

4.

A critical assessment of generic substitution for the obstetrician-gynecologist.

Keith LG, Oleszczuk JJ, Ahranjani M.

Int J Fertil Womens Med. 2001 Nov-Dec;46(6):286-95. Review.

PMID:
11795687
5.

[Bioequivalence studies of pharmaceutical preparations].

Vetchý D, Frýbortová K, Rabisková M, Danecková H.

Cas Lek Cesk. 2007;146(5):431-3. Review. Czech.

PMID:
17554963
6.
7.

Polymorphism in generic drug product development.

Snider DA, Addicks W, Owens W.

Adv Drug Deliv Rev. 2004 Feb 23;56(3):391-5. Review.

PMID:
14962588
8.

The impact of generic drugs on the cost of transplantation medical care.

Olyaei AJ, deMattos AM, Bennett WM.

Transplant Proc. 1999 May;31(3A Suppl):31S-34S. Review. No abstract available.

PMID:
10330957
9.

Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.

Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J.

Semin Thromb Hemost. 2008 Feb;34(1):74-85. doi: 10.1055/s-2008-1066026. Review.

PMID:
18393144
10.

Debate: Substitution of generic drugs in epilepsy: is there cause for concern?

Gidal BE, Tomson T.

Epilepsia. 2008 Dec;49 Suppl 9:56-62. doi: 10.1111/j.1528-1167.2008.01927.x. Review.

11.

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.

Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.

Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. doi: 10.1517/14656560903140525. Review.

PMID:
19663636
12.
13.

The value of specifying brand-name antiepileptic drugs.

Ng YT.

Arch Neurol. 2009 Nov;66(11):1415-6. doi: 10.1001/archneurol.2009.232. Review. No abstract available.

PMID:
19901176
14.

Generic antiarrhythmic drugs: what constitutes equivalency.

Benditt DG.

J Interv Card Electrophysiol. 1999 Jul;3(2):145-7. Review. No abstract available.

PMID:
10387141
15.

Generic drugs: the Canadian perspective.

McGilveray IJ, Gallicano K.

Transplant Proc. 1999 May;31(3A Suppl):16S-18S. Review. No abstract available.

PMID:
10330953
16.

Generic immunosuppressant use in solid organ transplantation.

Alloway RR.

Transplant Proc. 1999 May;31(3A Suppl):2S-5S. Review.

PMID:
10330948
17.

A review of the safety of generic drugs.

Dighe SV.

Transplant Proc. 1999 May;31(3A Suppl):23S-24S. Review.

PMID:
10330955
18.

Bioequivalence of antiepileptic drugs: how close is close enough?

Gidal BE.

Curr Neurol Neurosci Rep. 2009 Jul;9(4):333-7. Review.

PMID:
19515287
19.

[Bioequivalence of generic drugs].

Schwabe U.

Internist (Berl). 1988 Mar;29(3):147-59. Review. German. No abstract available.

PMID:
3288573

Supplemental Content

Support Center